Concerns Over Valeant Spread to Other Drug Makers

As questions mount about the viability of Valeant Pharmaceuticals International Inc.’s business model, writes the Wall Street Journal, concerns are spreading to other drug makers seen as following a similar playbook. Like Valeant, these firms are part of a new breed of pharmaceutical company that has limited costly investment in research and development and instead sought sales growth through debt-fueled acquisitions—often of older drugs for which they raise prices sharply.